The US FDA has completed an inspection of Lupin's injectable unit in Nagpur, which took place from June 10-13, 2024, resulting in zero observations. This marks a successful closure of the inspection for Lupin, as noted in an exchange filing. In contrast, Biocon's API facility (Site 6) in Visakhapatnam has received three observations from a recent US FDA inspection. Additionally, the US FDA has classified Zydus Life's injectable manufacturing unit at Pharmez SEZ, Matoda, as Official Action Indicated following an inspection conducted from March 18-27.
US FDA Classifies Zydus Life’s Injectable Mfg Unit At Pharmez SEZ, Matoda Unit As Official Action Indicated US FDA Conducted An Inspection At The Injectable Mfg Unit At Motada From March 18-27 https://t.co/g6WPP3EHw7
US FDA Classifies Zydus Life’s Injectable Mfg Unit At Pharmez SEZ, Matoda Unit As Official Action Indicated US FDA Conducted Inspection At Injectable Mfg Unit At Motada From from March 18-27 https://t.co/filGjDAlBI
#Biocon U.S. FDA inspection at Vishakhapatnam API facility ends with 3 observations: Exchange filing
#Biocon API facility in Visakhapatnam receives 3 observations from USFDA inspection https://t.co/v9Zgch9xsP
US FDA issues 3 observations for #Biocon's API facility (Site 6), located at Visakhapatnam, Andhra Pradesh https://t.co/ZaJFHYEjzI
US FDA isssues 3 observations for #Biocon's API facility (Site 6), located at Visakhapatnam, Andhra Pradesh https://t.co/lUGvx3Nmn1
Global pharma major Lupin announced that the United States Food and Drug Administration (USFDA) completed an inspection of its injectable facility in Nagpur, concluding with zero observations @koul_sanket #lupin #pharma #fda https://t.co/4LWSWcduV9
#ZydusLifesciences receives tentative approval from the U.S. FDA to market Azilsartan Medoxomil and Chlorthalidone tablets.
#Lupin announces closure of U.S. #FDA inspection at injectable facility with zero 483 observations: Exchange filing
News Alert | Lupin announces closure of USFDA inspection at its injectable facility with zero 483 observations @LupinIndia https://t.co/5CoGTFxaRO
#JustIN | US FDA issues form 483 with zero observations for #Lupin’s injectable unit in Nagpur, this marks the closure of inspection at the unit Injectable Unit In Nagpur was inspected by US FDA from June 10 -13, 2024 https://t.co/O8RFDktkTG